XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026)

XOMA Royalty (XOMA) reported Non-Current Deffered Revenue of $2.9 million for Q1 2026, down 29.97% on a YoY basis from $4.1 million in Q1 2025, and down 10.43% sequentially from $3.2 million in Q4 2025.

XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends

XOMA Royalty (XOMA) has 17 years of Non-Current Deffered Revenue data on file, last reported at $2.9 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 29.97% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (down 29.97% YoY), and the FY2025 full-year result was $3.2 million, down 27.6% from the prior year.
  • Non-Current Deffered Revenue declined to $2.9 million in Q1 2026, from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $11.3 million in Q1 2022 to a low of $2.9 million in Q1 2026.
  • A 5-year average of $6.9 million and a median of $7.0 million in 2023 frame the typical range for Non-Current Deffered Revenue.
  • Across the five-year window, Non-Current Deffered Revenue declined 13.59% in 2022 and tumbled 39.04% in 2025, its largest moves.
  • Tracing XOMA's Non-Current Deffered Revenue over 5 years: stood at $9.5 million in 2022, then decreased by 24.31% to $7.2 million in 2023, then plunged by 38.99% to $4.4 million in 2024, then decreased by 27.6% to $3.2 million in 2025, then decreased by 10.43% to $2.9 million in 2026.
  • Business Quant data shows XOMA's Non-Current Deffered Revenue at $2.9 million in Q1 2026, $3.2 million in Q4 2025, and $3.7 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 XOMA Royalty 478.42 Mn 412.34 Mn - 2.86 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.86 Mn
Dec 31, 2025 3.19 Mn
Jun 30, 2025 3.67 Mn
Mar 31, 2025 4.08 Mn
Dec 31, 2024 4.41 Mn
Sep 30, 2024 5.59 Mn
Jun 30, 2024 6.00 Mn
Mar 31, 2024 6.70 Mn
Dec 31, 2023 7.23 Mn
Sep 30, 2023 7.80 Mn
Jun 30, 2023 8.45 Mn
Mar 31, 2023 9.04 Mn
Dec 31, 2022 9.55 Mn
Sep 30, 2022 10.38 Mn
Jun 30, 2022 10.84 Mn
Mar 31, 2022 11.35 Mn
Dec 31, 2021 11.69 Mn
Sep 30, 2021 12.31 Mn
Jun 30, 2021 12.73 Mn
Mar 31, 2021 13.13 Mn